# Progress Note 05 — Focused Visit (Care-plan review)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Gwen Ifill (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML032-SYN-TD
- Date: 2016-06-30
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorna Achebe-Price, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Focused Visit (Care-plan review)

## Chief complaint

End of combination treatment: CT result, thyroid tests, and the first maintenance dose. **S**

## History of present illness

Ms. Ifill returns three weeks after her sixth and last cycle of combination treatment, all given on schedule. The CT a week ago shows no evidence of disease. Over the past month she has felt more tired than after earlier cycles, colder than usual, and a little slowed down, without low mood. The tingling in her toes is unchanged and does not affect walking. She has had no vaginal bleeding, pelvic pain, cough, breathlessness, diarrhea, rash, headache, dizziness or leg swelling. She saw Dr. Delacroix with the CT result and is ready to begin maintenance dostarlimab today. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Treatment | Six cycles of dostarlimab, carboplatin and paclitaxel completed on schedule |
| Response | CT: no evidence of disease |
| New symptoms | Tiredness and feeling cold for a month |
| Neuropathy | Grade 1, unchanged |
| Today | First maintenance dose of dostarlimab 1000 mg |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Tired and feels cold; no fever or weight loss |
| Genitourinary | Negative | No vaginal bleeding or discharge |
| Gastrointestinal | Negative | No diarrhea, constipation or abdominal pain |
| Respiratory | Negative | No cough or breathlessness |
| Neurological | Positive | Tingling in the toes, unchanged; no headache or dizziness |
| Endocrine | Positive | Cold intolerance; no thirst |
| Psychiatric | Negative | Mood good; PHQ-9 4; no thoughts of self-harm |

7 systems reviewed. **S**

## Current medications

- Dostarlimab 50 mg/mL injection, 1000 mg intravenously over 30 minutes every 6 weeks as maintenance, for up to three years **S**
- Levothyroxine 75 mcg oral tablet, one tablet daily before breakfast **S**

## Allergies

- No known allergy **S**

## Objective

BP 122/78 mmHg; pulse 64 bpm; respirations 16/min; temperature 36.4 °C; oxygen saturation 98% on room air; weight 72.4 kg; BMI 26.6 kg/m². All vital signs are synthetic.

Hemoglobin: 11.4 g/dL (low); White cell count: 4.9 10*3/uL; Absolute neutrophil count: 2.8 10*3/uL; Platelets: 228 10*3/uL; Creatinine: 0.84 mg/dL; eGFR (CKD-EPI 2011): 80 mL/min/1.73 m²; Glucose: 90 mg/dL; ALT: 22 U/L; AST: 24 U/L; Total bilirubin: 0.5 mg/dL; TSH: 11.8 mIU/L (high); Free T4: 0.7 ng/dL (low); Cortisol (morning): 13.1 ug/dL; PHQ-9: 4. All results are synthetic.

## Change since baseline

- Hemoglobin: 11.8 g/dL (low) at baseline, 11.4 g/dL (low) at this visit **S**
- White cell count: 6.2 10*3/uL at baseline, 4.9 10*3/uL at this visit **S**
- Platelets: 268 10*3/uL at baseline, 228 10*3/uL at this visit **S**
- Creatinine: 0.82 mg/dL at baseline, 0.84 mg/dL at this visit **S**
- eGFR (CKD-EPI 2011): 82 mL/min/1.73 m² at baseline, 80 mL/min/1.73 m² at this visit **S**
- Glucose: 94 mg/dL at baseline, 90 mg/dL at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well but tired; weight 72.4 kg; blood pressure 122/78, pulse 64, temperature 36.4 °C |
| Neck | Thyroid not enlarged or tender |
| Abdomen | Soft, non-tender; no mass |
| Extremities | No leg swelling; calf circumferences unchanged |
| Neurological | Pinprick slightly reduced over the toes only; ankle reflexes present with a slow relaxation phase; steady gait |
| Psychiatric | Alert and engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Endometrioid endometrial cancer, stage IIIC2ii, MMRd, no evidence of disease after combination treatment** (C54.1). No evidence of disease on CT, so radiation is not needed. Maintenance dostarlimab continues every six weeks for up to three years. Counts have recovered: hemoglobin 11.4 g/dL, neutrophils 2.8, platelets 228. Kidney and liver function and glucose are normal. Dr. Delacroix and she agreed today's plan. **S**
   - Dostarlimab 1000 mg today, then every six weeks.
   - Survivorship care plan given: examination with a pelvic examination every three months for two years; CT every six months for three years; no routine vaginal cytology and no CA-125.
   - Report vaginal bleeding, pelvic or abdominal pain, cough, weight loss or leg swelling.
2. **Immune-related primary hypothyroidism, grade 2** (E03.2). TSH 11.8 with free T4 0.7, below range, and tiredness, feeling cold and a slower pulse: primary hypothyroidism from dostarlimab, the most common immune-related endocrine effect. Morning cortisol 13.1 is normal, so adrenal insufficiency is not the cause of her tiredness and thyroid replacement can start safely. Dostarlimab can continue with replacement. **S**
   - Levothyroxine 75 mcg daily before breakfast, starting today.
   - TSH and free T4 in six weeks, then with every dose.
   - Thyroid hormone will probably be needed long term.
3. **Chemotherapy-induced peripheral neuropathy, grade 1** (G62.0). Stable after the last paclitaxel; expected to improve slowly. **S**
   - Review at each visit.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Response imaging (CT of the chest, abdomen and pelvis) | At the end of combination treatment | Up to date | A week ago: no evidence of disease |
| Laboratory | Blood count with neutrophils and platelets | Before each cycle; at the end of treatment | Completed today | Hemoglobin 11.4 g/dL, white cells 4.9, neutrophils 2.8, platelets 228; recovered |
| Laboratory | Creatinine and estimated kidney function | Before each checkpoint inhibitor dose | Completed today | Creatinine 0.84 mg/dL, eGFR 80 |
| Laboratory | Liver tests (paclitaxel and checkpoint inhibitor) | Baseline and before each checkpoint inhibitor dose | Completed today | ALT 22, AST 24 U/L, bilirubin 0.5 mg/dL |
| Laboratory | TSH and free T4 (immune-related thyroid disease) | Baseline and before each checkpoint inhibitor dose | Completed today | TSH 11.8 mIU/L and free T4 0.7 ng/dL: immune-related hypothyroidism; levothyroxine started |
| Laboratory | Glucose (immune-related diabetes) | Baseline and before each checkpoint inhibitor dose | Completed today | 90 mg/dL |
| Laboratory | Morning cortisol (immune-related adrenal and pituitary disease) | Baseline and before each checkpoint inhibitor dose | Completed today | 13.1 ug/dL, normal; drawn before 9 a.m. under the standing order |
| Laboratory | CA-125 | Only if raised at diagnosis | Not indicated | Normal at diagnosis (28 U/mL) |
| Examination | Peripheral neuropathy: symptoms and examination | At each visit after taxane treatment | Completed today | Grade 1, stable |
| Examination | Lymphedema | Each visit after lymph node surgery | Completed today | No swelling |
| Examination | Immune-related adverse event symptoms (diarrhea, rash, cough, breathlessness, fatigue, headache) | Each visit on a checkpoint inhibitor | Completed today | Tiredness and cold intolerance, explained by hypothyroidism; no diarrhea, rash, cough or headache |
| Examination | Pelvic examination | Every three months for two years | Due | With gynecologic oncology in three months |
| Imaging | Surveillance CT of the chest, abdomen and pelvis | Every six months for three years for stage III disease | Due | Next in six months |
| Medication safety | Levothyroxine: timing and interactions | At the start | Completed today | Take on an empty stomach before breakfast, four hours apart from calcium or iron |
| Survey | Distress and depression screen (PHQ-9) | At diagnosis, each treatment phase, and when symptoms change | Completed today | PHQ-9 4 |
| Self-management | Survivorship care plan | At the end of active treatment | Completed today | Written plan: visit schedule, symptoms of recurrence to report, lymphedema signs, weight and activity, blood pressure, lipid and glucose care, and screening for other cancers |

## Goal progress

- Endometrial tissue diagnosis and ultrasound within one week, and a gynecologic oncology plan within three weeks of presentation. Outcome by 2016-01-20: Biopsy at the first visit, ultrasound in two days, result in four days, CT in eight, consultation at two weeks. **S**
- Surgical staging within four weeks of diagnosis. Outcome by 2016-02-24: Minimally invasive hysterectomy with sentinel node mapping and para-aortic node removal two weeks after the consultation. **S**
- Six cycles of dostarlimab with carboplatin and paclitaxel every three weeks without a delay of more than one week. Outcome by 2016-06-30: Six cycles on schedule; CT shows no evidence of disease. **S**
- Lynch syndrome tumor screening completed and explained before treatment starts. Outcome by 2016-02-24: MLH1 promoter hypermethylation found: acquired, not inherited; genetic counseling done. **S**
- Immune-related adverse events found early: TSH, liver tests, glucose and cortisol checked on schedule. Outcome by 2016-06-30: Hypothyroidism found on a scheduled TSH and treated without stopping dostarlimab; one missed baseline cortisol recorded and corrected. **S**
- PHQ-9 below 10 throughout treatment, with support she chooses. Outcome by 2016-06-30: PHQ-9 between 4 and 6. **S**

## Medication changes

- Stopped: Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**
- Started: Dostarlimab 50 mg/mL injection, 1000 mg intravenously over 30 minutes every 6 weeks as maintenance, for up to three years **S**
- Started: Levothyroxine 75 mcg oral tablet, one tablet daily before breakfast **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026), National Comprehensive Cancer Network
- Mirza MR, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY). N Engl J Med 2023;388(23):2145-2158 (PMID 36972026) (2023), New England Journal of Medicine
- JEMPERLI (dostarlimab-gxly) injection, prescribing information (2026), U.S. National Library of Medicine, DailyMed (GlaxoSmithKline label)
- Salani R, et al. Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol 2026;204:109-117 (PMID 41308226) (2026), Society of Gynecologic Oncology
- Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021), American Society of Clinical Oncology
- Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020), American Society of Clinical Oncology
- CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Preventive visit in six weeks with TSH and free T4, on the day of the second maintenance dose. Gynecologic oncology examination in three months; CT in six months. Call for vaginal bleeding, pelvic pain, cough, diarrhea, rash or breathlessness. **S**
- Next scheduled visit 2016-08-11: periodic adult preventive visit. **S**
